First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 509 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Time to take on 9 new Cancer Grand Challenges March 8, 2023 Free Rides to Screening Appointments Thanks to Woman Who Lost Mother... May 16, 2019 We want every scientist to thrive in cancer research July 28, 2023 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers January 21, 2022 Load more HOT NEWS FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Cancer Research UK appoints new Trustees and independent Committee Members Female Representation at the Top of the Oncology Field Has Hit... Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among...
